Literature DB >> 18705550

Argatroban in short-term percutaneous ventricular assist subsequent to heparin-induced thrombocytopenia.

David P Webb1, Matthew T Warhoover, Susan S Eagle, James P Greelish, David X Zhao, John G Byrne.   

Abstract

Heparin-induced thrombocytopenia paradoxically is a transient pro-thrombotic disorder triggered by heparin exposure. If not treated appropriately, it can be life threatening because of its related thromboembolic complications. In particular, it presents a unique challenge in patients needing extracorporeal life support, because anticoagulation is essential for safe management. This case report describes the safe, efficacious use of Argatroban during short-term support of a patient with a percutaneously inserted left ventricular assist TandemHeart device.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18705550      PMCID: PMC4680635     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  17 in total

Review 1.  Argatroban.

Authors:  Sekar Kathiresan; Jin Shiomura; Ik-Kyung Jang
Journal:  J Thromb Thrombolysis       Date:  2002-02       Impact factor: 2.300

Review 2.  Heparin-induced thrombocytopenia: pathogenesis and management.

Authors:  Theodore E Warkentin
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

3.  Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial.

Authors:  Andreas Koster; Semi Buz; Roland Hetzer; Hermann Kuppe; Klaus Breddin; Sebastian Harder
Journal:  J Thorac Cardiovasc Surg       Date:  2006-09       Impact factor: 5.209

Review 4.  Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery.

Authors:  Glenn S Murphy; Jesse H Marymont
Journal:  J Cardiothorac Vasc Anesth       Date:  2006-10-24       Impact factor: 2.628

Review 5.  Cardiac failure: mechanical support strategies.

Authors:  John P Boehmer; Eric Popjes
Journal:  Crit Care Med       Date:  2006-09       Impact factor: 7.598

6.  Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.

Authors:  Bruce E Lewis; Diane E Wallis; Marcie J Hursting; Robert L Levine; Fred Leya
Journal:  Chest       Date:  2006-06       Impact factor: 9.410

7.  Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery.

Authors:  T L Bauer; G Arepally; B A Konkle; B Mestichelli; S S Shapiro; D B Cines; M Poncz; S McNulty; J Amiral; W W Hauck; R N Edie; J D Mannion
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

8.  Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock.

Authors:  Holger Thiele; Peter Sick; Enno Boudriot; Klaus-Werner Diederich; Rainer Hambrecht; Josef Niebauer; Gerhard Schuler
Journal:  Eur Heart J       Date:  2005-02-25       Impact factor: 29.983

9.  Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia.

Authors:  Brian Mejak; Carmen Giacomuzzi; Eileen Heller; Xiaomang You; Ross Ungerleider; Irving Shen; Lynn Boshkov
Journal:  J Extra Corpor Technol       Date:  2004-06

Review 10.  Small-molecule direct antithrombins: argatroban.

Authors:  Jawed Fareed; Walter P Jeske
Journal:  Best Pract Res Clin Haematol       Date:  2004-03       Impact factor: 3.020

View more
  1 in total

Review 1.  Heparin induced thrombocytopenia with mechanical circulatory support devices: review of the literature and management considerations.

Authors:  Jonathan Bain; Alexander H Flannery; Jeremy Flynn; William Dager
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.